Champions Oncology Inc. (CSBR)
NASDAQ: CSBR
· Real-Time Price · USD
7.50
0.53 (7.60%)
At close: Aug 19, 2025, 1:15 PM
7.60% (1D)
| Bid | 7.32 |
| Market Cap | 103.33M |
| Revenue (ttm) | 44.59M |
| Net Income (ttm) | 4.7M |
| EPS (ttm) | 0.33 |
| PE Ratio (ttm) | 22.73 |
| Forward PE | 29.5 |
| Analyst | Strong Buy |
| Ask | 7.54 |
| Volume | 63,161 |
| Avg. Volume (20D) | 33,545 |
| Open | 7.02 |
| Previous Close | 6.97 |
| Day's Range | 7.02 - 7.73 |
| 52-Week Range | 3.60 - 11.99 |
| Beta | 0.46 |
About CSBR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CSBR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CSBR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Champions Oncology Inc. is scheduled to release its earnings on
Sep 10, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-14.19%
Champions Oncology shares are trading lower. The c...
Unlock content with
Pro Subscription
8 months ago
+12.09%
Champions Oncology shares are trading higher after the company reported a year-over-year increase in Q2 financial results.
3 weeks ago · accessnewswire.com
Champions Oncology Reports Record Annual Revenue of $57 MillionTotal annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced it...
2 months ago · seekingalpha.com
Champions Oncology: Biological IP Is The Real Asset - Not Preclinical ServicesChampions Oncology is transitioning from a traditional CRO to also a high-margin data licensing platform, unlocking new revenue and margin potential. The market undervalues CSBR, not reflecting its ev...